Pfizer's Pitch For Chantix Warning Reduction Focuses On Those With Mental Illness
Executive Summary
Those patients need more options for smoking cessation, Pfizer says, but that is the group FDA most worries about when deciding whether to remove its boxed warning.
You may also be interested in...
Do Black Boxes Work? US FDA Survey Would Test Impact On Prescribers
Depending on who you ask, black box warnings can fail to curb inappropriate prescribing or scare off patients who would benefit from an effective therapy. FDA is proposing a provider survey to find out what perceptions really are.
Do Black Boxes Work? US FDA Survey Would Test Impact On Prescribers
Depending on who you ask, black box warnings can fail to curb inappropriate prescribing or scare off patients who would benefit from an effective therapy. FDA is proposing a provider survey to find out what perceptions really are.
FDA Makes Rare Call, Removes Boxed Warning From Chantix, Zyban Labels
Pfizer, GSK score as neuropsychiatric symptom risks now only appear in Warnings and Precautions section following EAGLES trial results.